The Use of Intravenous Immunoglobulins (IVIG) in Immunological Mediated Diseases and Possible Mechanisms of Actions

Angel Alberto Justiz Vaillant^1, , Sehlule Vuma¹ and Wayne Mohammed¹

¹Pathology and Microbiology Unit, Department of Para-Clinical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago, WI

Cite this paper:
Angel Alberto Justiz Vaillant, Sehlule Vuma and Wayne Mohammed. The Use of Intravenous Immunoglobulins (IVIG) in Immunological Mediated Diseases and Possible Mechanisms of Actions. American Journal of Pharmacological Sciences. 2015; 3(2):33-37. doi: 10.12691/ajps-3-2-1

Abstract

Intravenous immunoglobulin (IVIG) is a product prepared from fractionation of pools of thousands of plasma donations collected at blood transfusion services. IVIG has been used in the treatment of neurological disorders, primary and secondary immunodeficiency, skin disorders, autoimmune disorders, immunologic abortion, and as anti-cancer and anti-inflammatory therapy. In this paper we listed a number of diseases for which the use of IVIG has been successful and the most mentioned mechanisms of actions of this immunotherapy. IVIG has different modes of actions involving interference with activation of complement components and the cytokine network; effects on regulatory T cells (Tregs) subset; expression of Fc receptors; modulation of idiotype network; and activation, proliferation and effector functions of B and T lymphocytes and of antigen-presenting cells such as dendritic cells and macrophages. We concluded that IVIG has proven to be efficacious in the treatment of immunodeficiency, autoimmunity, infections and inflammatory disorders over the last three decades. To date IVIG has been used to treat more than 80 diseases. Although some of the mechanisms of actions of IVIG are obscure in nature, the fact that many patients improved with it when all other options of treatment were exhausted, make the use of IVIG an important alternative. On the other hand, treatment with IVIG is expensive. We are hopeful that in near future new horizons will be open for the acquisition and use of a cheaper IVIG to treat weak immune system or as immunosuppressive drug in the treatment of autoimmune and inflammatory disorders.

Keywords:
intravenous immunoglobulins (IVIG) immunological diseases immunotherapy autoimmunity immunodeficiency

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011 Jun; 7(6): 349-59.
[2]	Timmerman PR. Intravenous immunoglobulin in oncology nursing practice. Oncol Nurs Forum. 1993 Jan-Feb; 20(1): 69-75.
[3]	Lemieux R, Bazin R, Néron S. Therapeutic intravenous immunoglobulins. Mol Immunol. 2005 May; 42 (7): 839-48.
[4]	Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P, Mouthon L. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. BioDrugs. 2002; 16(1): 47-55.
[5]	Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol. 2008 Jul; 255 Suppl 3:3-6.
[6]	Sapir T, Shoenfeld Y. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol. 2005 Dec; 29(3):185-99.
[7]	Mouthon L, Bussone G, Kaveri S. Indications and mechanisms of action of the intravenous immunoglobulines in the systemic autoimmune and inflammatory pathologies. Rev Med Interne. 2009 Dec; 30(12 Suppl):H14-20.
[8]	Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology (Oxford). 2015 Mar; 54 (3): 383-391.
[9]	Feasby T, Banwell B, Benstead T, Bril V, Brouwers M, Freedman M, Hahn A, Hume H, Freedman J, Pi D, Wadsworth L. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007 Apr; 21(2 Suppl 1):S57-107.
[10]	Hara M. Intravenous immunoglobulin (IVIG). Nihon Rinsho. 2009 Mar; 67(3):599-605.
[11]	Duff K. You can make a difference in the administration of intravenous immunoglobulin therapy. J Infus Nurs. 2006 May-Jun; 29(3 Suppl): S5-14.
[12]	Hurez V, Kaveri SV, Kazatchkine MD. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases. J Autoimmun. 1993 Dec; 6(6):675-81.
[13]	Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve. 2003 Apr; 27(4):407-25.
[14]	Dalakas MC. Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol. 2003 Jun; 23(2):199-206.
[15]	Mastaglia FL. Inflammatory muscle diseases. Neurol India. 2008 Jul-Sep; 56(3):263-70.
[16]	Kazatchkine M, Mouthon L, Kaveri SV. Immunomodulatory effects of intravenous immunoglobulins. Ann Med Interne (Paris). 2000 May;151 Suppl 1:1S13-8.
[17]	Sapir T, Shoenfeld Y. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol. 2005 Dec;29(3):185-99.
[18]	Sapir T, Shoenfeld Y. Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy. Clin Rev Allergy Immunol. 2005 Dec;29(3):307-10.
[19]	Sapir T, Carp H, Shoenfeld Y. Intravenous immunoglobulin (IVIG) as treatment for recurrent pregnancy loss (RPL). Harefuah. 2005 Jun;144(6):415-20.
[20]	Stricker RB, Winger EE. Update on treatment of immunologic abortion with low-dose intravenous immunoglobulin. Am J Reprod Immunol. 2005 Dec;54(6):390-6.
[21]	Emmi L, Chiarini F. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci. 2002 Apr;23 Suppl 1:S1-8.
[22]	Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011 Feb;127(2):315-23; quiz 324-5.
[23]	Imbach P, Lazarus AH, Kühne T. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang. 2010 Apr;98 (3 Pt 2):385-94.
[24]	Imbach P. Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review. Swiss Med Wkly. 2012 May 31;142:w13593.
[25]	Sibéril S, Elluru S, Negi VS, Ephrem A, Misra N, Delignat S, Bayary J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci. 2007 Aug;37(1):103-7.
[26]	Kasztalska K, Ciebiada M, Górski P. Mechanism of action of immunoglobulin applied intravenously. Pol Merkur Lekarski. 2010 Oct;29(172):263-8.
[27]	Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci. 2005 Jun;1051:743-78.
[28]	Ephrem A, Misra N, Hassan G, Dasgupta S, Delignat S, Duong Van Huyen JP, Chamat S, Prost F, Lacroix-Desmazes S, Kavery SV, Kazatchkine MD. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin Exp Med. 2005 Dec;5(4):135-40.
[29]	Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol. 2005 Apr;66(4):395-402.
[30]	Vani J, Elluru S, Negi VS, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev. 2008 Jun;7(6):440-4.
[31]	Mouthon L, Berezné A, Le Guern V, Guillevin L. Intravenous immunoglobulins: therapeutic indications. Presse Med. 2005 Sep 24; 34(16 Pt 1):1166-75.
[32]	Misra N, Bayry J, Ephrem A, Dasgupta S, Delignat S, Duong Van Huyen JP, Prost F, Lacroix-Desmazes S, Nicoletti A, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. J Neurol. 2005 May;252 Suppl 1:I1-6.
[33]	Michael D, Grando SA. Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses. Curr Dir Autoimmun. 2008;10:333-43.
[34]	Mittmann N, Chan BC, Knowles S, Shear NH. IVIG for the treatment of toxic epidermal necrolysis. Skin Therapy Lett. 2007 Feb;12(1):7-9.
[35]	Teo L, Tay YK, Liu TT, Kwok C. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options. Singapore Med J. 2009 Jan;50(1):29-33.
[36]	Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008 Jan 15;111(2):715-22.
[37]	Tjon AS, Tha-In T, Metselaar HJ, van Gent R, van der Laan LJ, Groothuismink ZM, te Boekhorst PA, van Hagen PM, Kwekkeboom J. Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clin Exp Immunol. 2013 Aug;173(2):259-67.
[38]	Hirabayashi Y, Takahashi Y, Xu Y, Akane K, Villalobos IB, Okuno Y, Hasegawa S, Muramatsu H, Hama A, Kato T, Kojima S. Lack of CD4⁺CD25⁺FOXP3⁺ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease. Eur J Pediatr. 2013 Jun;172(6):833-7.
[39]	Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev. 1989 Aug;110:135-49.
[40]	Dietrich G, Kaveri SV, Kazatchkine MD. Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S73-81.
[41]	Lacroix-Desmazes S, Mouthon L, Spalter SH, Kaveri S, Kazatchkine MD. Immunoglobulins and the regulation of autoimmunity through the immune network. Clin Exp Rheumatol. 1996 May-Jun;14 Suppl 15:S9-15.
[42]	Mouthon L, Kaveri S, Kazatchkine M. Immune modulating effects of intravenous immunoglobulin (IVIg) in autoimmune diseases. Transfus Sci. 1994 Dec;15(4):393-408.
[43]	Guilpain P, Chanseaud Y, Tamby MC, Larroche C, Guillevin L, Kaveri SV, Kazatchkine MD, Mouthon L. Immunomodulatory effects of intravenous immunoglobulins. Presse Med. 2004 Oct 9;33(17):1183-94.
[44]	Bayry J, Misra N, Latry V, Prost F, Delignat S, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003 Jun;10(3):165-9.
[45]	Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol. 1996 May;104 Suppl 1:3-9.
[46]	Ibáñez C, Montoro-Ronsano JB. Intravenous immunoglobulin preparations and autoimmune disorders: mechanisms of action. Curr Pharm Biotechnol. 2003 Aug;4(4):239-47.
[47]	Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45.
[48]	Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity. 2009 Sep;42(6):553-60.
[49]	Galeotti C, Maddur MS, Kazatchkine MD, Mouthon L, Kaveri SV. Intravenous immunoglobulins in autoimmune and inflammatory disorders: beyond a simple substitution. Transfus Clin Biol. 2009 May;16(2):75-9.
[50]	Lacroix-Desmazes S, Kaveri S, Kazatchkine MD. Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins (IgIV). Rev Neurol (Paris). 1996 May;152(5):349-54.
[51]	Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, Kaveri SV. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol. 2010 May; 30 Suppl 1:S4-8
[52]	Yen MH, Huang YC2, Chen MC3, Liu CC4, Chiu NC5, Lien R6, Chang LY7, Chiu CH6, Tsao KC8, Lin TY9. Effect of intravenous immunoglobulin for neonates with severe enteroviral infections with emphasis on the timing of administration. J Clin Virol. 2015 Mar;64:92-6.
[53]	Capasso L, Borrelli A, Cerullo J, Pisanti R, Figliuolo C, Izzo F, Paccone M, Ferrara T Lama S1, Raimondi F. Role of immunoglobulins in neonatal sepsis. Transl Med UniSa. 2014 Dec 19;11:28-33.
[54]	Basta M, Branch DR. 7th International Immunoglobulin Conference: Mechanisms of action. Clin Exp Immunol. 2014 Dec;178 Suppl 1:87-8.
[55]	Jimenez-Rivera C, Gupta A, Feberova J, de Nanassy JA, Boland MP. Successful treatment of neonatal hemochromatosis as gestational alloimmune liver disease with intravenous immunoglobulin. J Neonatal Perinatal Med. 2014;7(4):301-4.
[56]	Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008 Jan;58(1):15-25.